Last updated: 2026-09-08 09:12:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Design Therapeutics, Inc. (DSGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.14, with a market capitalization of $947.49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.28 to $17.25. This page covers its latest market performance, valuation, price trends and company information.
$947.49M | |
$14.96 | |
$50.50 | |
$1.94 | |
$15.03 | |
206.28K | |
683.88K | |
-- | |
$17.25 | |
$5.28 | |
-- | |
-- |
Design Therapeutics, Inc. (DSGN) is trading at $14.40 in pre-market trading as of 2026-09-04 23:31:00, down 4.19% ($0.63) from the previous close of $15.03
Pre-market trading shows how investors are pricing DSGN before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Design Therapeutics, Inc. (DSGN) moved from $15.25 to $15.14, representing a decline of 0.75% ($0.12).
The stock traded between $14.38 and $15.79 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 575.35 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.3%
DSGN is currently trading at $15.14, placing it 82.3% of the way from its 52-week low of $5.28 to its 52-week high of $17.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Design Therapeutics, Inc. (DSGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.